All News

Purpose directs the energy outward, and when tied to a beneficent cause, the experience is that of being connected to a deeper source— worry for self becomes compassion for others.

How can we relax and move forward when cancer and COVID-19 take up so much of our day?

The Food and Drug Administration approved the targeted therapy Tukysa as part of a drug combination to treat HER2-positive breast cancer. Here’s what you need to know.

As quarantine and social distancing wears on, one cancer survivor muses on the little things that have gone missing.

From a skin cancer survivor raising money for the fight against the novel coronavirus to a Cleveland Browns fan who has survived a rare brain tumor helping to open the broadcast of Thursday’s NFL Draft, here’s what is making headlines in the cancer space this week.

With the growing and evolving field of T-cell therapies, patients with metastatic melanoma have new hopes for effective treatment, but the treatment faces future clinical challenges.

A newly-diagnosed patient talks about her experience of being diagnosed with breast cancer amidst the COVID-19 pandemic.

With so many cancer survivors working at home during the COVID-19 pandemic, we may need to assess how our shift to computer-based work affects limbs with lymphedema and make a few adjustments to the new routines to help ourselves out.

The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.

Cancer alters the trajectory of your career, but it doesn't have to end it. Here are some ways to find resources that help patients and survivors alike find the next step of their careers.

The Food and Drug Administration, under its global Project Orbis, approved the combination of Imbruvica and Rituxan for patients with CLL and SLL.

It may feel obvious to cancer survivors and patients with cancer, but insomnia and cancer go hand in hand. Here are some tips to handle insomnia.

The Food and Drug Administration’s approval of Imfinzi (durvalumab) in combination with certain standard-of-care chemotherapies in extensive-stage small cell lung cancer offers an exciting option, but doesn’t quite change treatment, according to Dr. Jorge Gomez.

Calquence (acalabrutinib) may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia, according to the updated phase 2 results of an ongoing study.

Traditionally, it is the younger generations that become caregivers first. But cancer alters the best-laid plans.

Stay connected during these challenging times and keep up with all the news and updates from Susan G. Kommen Greater NYC by signing up for our latest newsletter!

Dealing with isolation is not new for widows and widowers who lost their spouses to cancer.

Save the date! We invite you to join CURE for our next monthly #CureConnect Tweet Chat on Thursday, April 30, at 1 p.m. EST, when we plan on discussing the costs of cancer.

During cancer it's easy to let friends in the "outside world" fall to the wayside, but it's sometimes possible, and helpful, to foster those relationships.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

The Food and Drug Administration approved Tukysa, which is indicated for use with two other drugs after patients have completed treatment with prior therapies targeting the protein HER2.

First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.

Even with an injured trust in the world, it's important to remember the lessons that help us move through cancer and other life traumas amid the COVID-19 pandemic.

From a woman with stage 4 colon cancer deciding to stream her wedding on Zoom to a patient with breast cancer sewing masks for at-risk groups across the United States, here’s the cancer news and updates happening amid the COVID-19 pandemic.

A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses.

Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

Thrivership and resilience are what we can gain from adversity and help us cope with change.

The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.